Amlexanox vs Retatrutide
A side-by-side research comparison of Amlexanox and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Amlexanox | Retatrutide |
|---|---|---|
| Full name | Amlexanox (TBK1/IKKε Inhibitor) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research / Off-label | Phase 3 Clinical Trial |
| Mechanism | Inhibits IKKε and TBK1 kinases that are upregulated in obesity, which normally suppress energy expenditure. Blocking these kinases restores thermogenesis and improves insulin sensitivity. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 298.29 Da | 5,200 Da (approximate) |
| Half-life | ~3-4 hours | 6 days |
| Bioavailability | ~70% oral | High (SubQ) |
| Typical dose | 25-100 mg | 1-2 mg → titrate up to 12 mg |
| Frequency | 3x daily | Once weekly |
| Route | Oral tablet | Subcutaneous injection |
Amlexanox reported benefits
- Increased energy expenditure
- Improved insulin sensitivity
- Weight loss
- Reduced inflammation
- Metabolic reset
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.